4/29/2020 Hichens Closes $100 Million Dollar Ventilator Deal With Brazil

Cognizance Biomarkers was awarded, on September 18, 2019, a $562,000 grant from the US National Institute of Health (NIH) for initiation of a clinical trial with the world renowned Mayo Clinic to confirm it's blood based protein biomarker test and algorithm accurately distinguishes epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES).  Dr. Greg Cascino, well known in the Epilepsy physician community is the Enterprise Director of Epilepsy at Mayo Clinic, has published over 200 peer-reviewed articles, presented approximately 400 invited lectures, and will serve as the Principal investigator of the trial.  The clinical trial protocol received full approval from the Mayo Clinic Investigational Review Board (IRB), and trial initiated on November 8, 2019.